Analyst Price Targets — DFTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 8, 2026 11:05 am | — | Stifel Nicolaus | $60.00 | $44.48 | TheFly | Definium Therapeutics price target raised to $60 from $30 at Stifel |
| June 30, 2026 11:04 am | — | Canaccord Genuity | $58.00 | $46.55 | TheFly | Definium Therapeutics price target lowered to $58 from $60 at Canaccord |
| June 23, 2026 11:23 am | Ami Fadia | Needham | $50.00 | $36.67 | StreetInsider | Definium Therapeutics Inc (DFTX) PT Raised to $50 at Needham |
| June 22, 2026 5:33 pm | — | Canaccord Genuity | $60.00 | $38.11 | TheFly | Definium Therapeutics price target raised to $60 from $38 at Canaccord |
| June 22, 2026 3:38 pm | — | Oppenheimer | $60.00 | $37.95 | TheFly | Definium Therapeutics price target raised to $60 from $40 at Oppenheimer |
| June 22, 2026 2:20 pm | Marc Goodman | Leerink Partners | $52.00 | $37.91 | StreetInsider | Definium Therapeutics Inc (DFTX) PT Raised to $52 at Leerink |
| May 8, 2026 11:05 am | David Amsellem | Piper Sandler | $48.00 | $23.20 | TheFly | Definium Therapeutics price target lowered to $48 from $49 at Piper Sandler |
| April 23, 2026 12:57 pm | — | Oppenheimer | $40.00 | $22.93 | TheFly | Definium Therapeutics price target raised to $40 from $25 at Oppenheimer |
| April 16, 2026 8:22 pm | Paul Matteis | Stifel Nicolaus | $30.00 | $22.46 | TheFly | Definium Therapeutics initiated with a Buy at Stifel |
| April 16, 2026 10:20 am | Sumant Kulkarni | Canaccord Genuity | $38.00 | $22.15 | TheFly | Definium Therapeutics price target raised to $38 from $25 at Canaccord |
Latest News for DFTX
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the launch of Wired for Worry, a new healthcare provider disease education initiative focused on generalized anxiety disorder (GAD). Wired for…
The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Definium Therapeutics, Inc. (DFTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today announced results from a new healthcare claims study of treatment patterns of newly diagnosed and established GAD patients, including…
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to eight newly hired non-executive employees consisting of options to purchase an aggregate of 169,740 common…
Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026. NEW YORK and TORONTO, June 26, 2026 /PRNewswire/ -- USA News Group News…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DFTX.
U.S. House Trading
No House trades found for DFTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.